Promedior Inc., a privately held clinical-stage biotechnology company based in Lexington, Massachusetts, has agreed to be acquired by Roche (RHHBY) in a deal with total transaction value of up to $1.39 billion. Roche will make an upfront cash payment of $390 million, plus additional contingent payments of up to $1 billion.
With the acquisition, Roche will obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151. Promedior has successfully advanced PRM-151 in human clinical trials and received Breakthrough Therapy Designation from the FDA earlier in the current year for idiopathic pulmonary fibrosis.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.